FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 628 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial. PMID 34728786 · Bone Marrow Transplant · 2022-Feb The study is a randomized Phase III oncology trial with a drug intervention (conditioning chemotherapy), but the primary efficacy endpoint is a continuous outcome measure (Oral Mucositis Assessment Scale score), not a time-to-event endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) reported with Kaplan-Meier or hazard ratios. Therefore, it does not meet the cohort's requirement for a time-to-event primary/key secondary endpoint. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Association between biomarkers of tobacco consumption and lung cancer risk among daily smokers. PMID 34651540 · Expert Rev Respir Med · 2022-Feb The study is an oncology-related Phase III clinical trial report in humans with original results, but it does not involve a drug-containing intervention (it assesses salivary biomarkers for risk stratification) and does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) or Kaplan-Meier/HR analysis. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial. PMID 36550442 · BMC Cancer · 2022-Dec-22 The record is a published erratum for a Phase III randomized trial of a drug (P013, a pertuzumab biosimilar) in human HER2-positive breast cancer. However, the abstract is empty, and the provided metadata indicates no signal for a time-to-event endpoint (OS, PFS, DFS, etc., Kaplan-Meier, or HR). A published erratum is not an original result report. Therefore, it does not meet the criteria for inclusion as an original formal-result report of a trial with a primary/key secondary time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Long-Term Methimazole versus Radioactive Iodine in the Treatment of Toxic Multinodular Goiter. PMID 36415961 · Endocrinol Metab (Seoul) · 2022-Dec The study is a randomized trial comparing methimazole vs. radioactive iodine in toxic multinodular goiter (thyroid neoplasm). However, it does not report a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier estimate, or hazard ratio). The primary outcomes are time to euthyroidism and proportion of time spent euthyroid, which are not survival/recurrence outcomes. Therefore, it does not meet the inclusion criteria. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study. PMID 36223695 · Breast · 2022-Dec The record describes a Phase III randomized trial, but its primary endpoints are pharmacokinetic (bioavailability) and patient preference, with no reported time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier). Therefore, it does not meet the criterion for a primary/key secondary time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B. PMID 35985545 · J Hepatol · 2022-Dec The report is eligible as an original randomized trial with a primary time-to-event endpoint in oncology, but it is excluded because the intervention is not exclusively drug-containing (includes a traditional Chinese medicine compound) and the trial phase is not definitively established as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant. PMID 35794705 · Hematol Oncol · 2022-Dec The record is a network meta-analysis summarizing multiple trials, not an original report of a single randomized trial with a primary time-to-event efficacy endpoint. While it discusses oncology, human, randomized, and drug interventions, the abstract does not explicitly identify a time-to-event endpoint (e.g., OS, PFS) or Kaplan-Meier/HR as the primary outcome, and the publication type is a review/meta-analysis, not an original trial result. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. PMID 35679476 · Blood · 2022-Aug-25 The record describes a comparative effectiveness analysis of ZUMA-5 (axi-cel) versus an external control (SCHOLAR-5). While it reports results from the pivotal ZUMA-5 trial, the metadata does not explicitly confirm the trial phase (Phase III/IIIb or II/III) or that it was a randomized controlled trial. The abstract mentions 'pivotal ZUMA-5 trial' and eligibility criteria simulating RCT conditions, but the comparison is against an external historical cohort, not a concurrent randomized control arm within the same trial. Therefore, the key criteria of randomized phase 3/definitive evidence cannot be definitively established from the provided information. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| T-DXd: New Standard for HER2-Low Breast Cancer. PMID 35666611 · Cancer Discov · 2022-Aug-05 The record is an oncology Phase III human trial of a drug, but the provided abstract is a summary/news piece ('T-DXd: New Standard...'). It does not explicitly state randomized design or present primary time-to-event efficacy results (e.g., OS/PFS with HR/KM). Therefore, eligibility cannot be confirmed without the full primary formal report. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial. PMID 35771546 · JAMA Oncol · 2022-Aug-01 The record is a randomized clinical trial with a drug intervention and a primary time-to-event efficacy endpoint (PFS with HR) in human oncology, meeting all core criteria. The phase is not explicitly stated, but the trial design and primary analysis are consistent with a definitive randomized trial; therefore, is_eligible is set to true based on the available evidence, though phase metadata is incomplete. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial. PMID 35952316 · JCO Precis Oncol · 2022-Aug While the record confirms key criteria (Phase III, human, oncology, time-to-event endpoint, drug intervention, original result), the specific report is a secondary analysis focused on a biomarker (Immunoscore) for prognostication. This does not meet the requirement for a 'primary' or 'key secondary' efficacy report of the drug-containing intervention in a Phase III trial. Randomization is implied but not explicitly detailed in the abstract, though the trial is Phase III. Eligibility is set to null due to the secondary analysis nature and ambiguous randomization evidence. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial. PMID 35800292 · J Bone Oncol · 2022-Aug Eligibility cannot be definitively established because the trial phase is not explicitly reported in the provided metadata. The record is for a randomized clinical trial with a drug intervention and a time-to-event endpoint, but the phase (III/IIIb or II/III) is not confirmed, which is a required criterion. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Adjusting for treatment crossover in the MAVORIC trial: survival in advanced mycosis fungoides and Sézary syndrome. PMID 35678206 · J Comp Eff Res · 2022-Aug The record is from a randomized, oncology, human trial with a drug intervention and a time-to-event endpoint, but it is a secondary analysis (crossover adjustment) and the Phase III evidence is not confirmed in the metadata. Therefore, eligibility cannot be definitively established as true. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation. PMID 35610308 · Bone Marrow Transplant · 2022-Aug The record describes a Phase III randomized trial in human AML/MDS with a primary/key secondary time-to-event efficacy endpoint (PFS). The intervention arms involve fludarabine, busulfan, and clofarabine, which are drug therapies, making drug_intervention implicitly true based on the record content. However, the deterministic review flagged 'drug_intervention_unclear' and set the criterion to null due to insufficient explicit evidence in the provided metadata signals. The original result is present (final trial outcome with PFS and RI data). Is_eligible is set to null because the metadata cannot fully establish the drug_intervention criterion with the required explicit evidence from the provided fields. |
H
L
S
B
|
旧组与严格 v3 交集 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Impact of B-lines-guided intensive heart failure management on outcome of discharged heart failure patients with residual B-lines. PMID 35595501 · ESC Heart Fail · 2022-Aug The study is a heart failure management trial, not an oncology study. It lacks a drug-containing intervention (mentions drug utilization but not a specific drug intervention for cancer), does not have a time-to-event primary efficacy endpoint (composite of readmission and death is a clinical endpoint, not a Kaplan-Meier or time-to-event analysis per the specification), and is a protocol without results. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial. PMID 35388465 · Br J Haematol · 2022-Aug The record describes a randomized, drug-comparison trial in human oncology patients with a primary time-to-event efficacy endpoint (overall survival at five years). However, the formal trial phase (e.g., Phase II/III or Phase III) is not explicitly stated in the provided metadata (title, abstract, or publication types), which prevents definitive eligibility confirmation. Therefore, is_eligible is set to null. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Value of Reducing Wait Times for Chimeric Antigen Receptor T-Cell Treatment: Evidence From Randomized Controlled Trial Data on Tisagenlecleucel for Diffuse Large B-Cell Lymphoma. PMID 35341689 · Value Health · 2022-Aug The study is a health-economic/decision analysis using data from the JULIET trial to quantify the value of reducing treatment wait times. It does not report primary or key secondary time-to-event efficacy results (OS, PFS, DFS, etc.) from the randomized trial itself. The primary outcome is an indicator for abnormal LDH, not a time-to-event endpoint. Therefore, it does not meet the required criteria for inclusion in the Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Development and validation of a prediction model for in-hospital mortality of patients with severe thrombocytopenia. PMID 35428822 · Sci Rep · 2022-Apr-15 The record describes a retrospective study developing a predictive model for in-hospital mortality in ICU patients with severe thrombocytopenia. Although it has some oncology-related terms and involves human subjects, it does not meet the core criteria: it is not a randomized controlled trial of a drug intervention, it does not have a time-to-event efficacy endpoint (like OS, PFS), and it is not a Phase III or definitive trial. The study is a predictive model development and validation, not an efficacy report of a therapeutic intervention. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| [Efficacy and safety of IAC regimen for relapse/refractory acute myeloid leukemia: a prospective randomized controlled study]. PMID 35680626 · Zhonghua Xue Ye Xue Za Zhi · 2022-Apr-14 The record is a randomized, prospective clinical trial evaluating a drug-containing regimen (IAC) in human acute myeloid leukemia with an overall survival time-to-event endpoint. It reports original results. However, the provided metadata (including publication types and mesh terms) does not explicitly confirm the trial phase as Phase III/IIIb or Phase II/III; it is only marked as a 'Randomized Controlled Trial'. The criteria require explicit establishment of phase. Therefore, eligibility cannot be confirmed. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| AVOID; a phase III, randomised controlled trial using indocyanine green for the prevention of anastomotic leakage in colorectal surgery. PMID 35365509 · BMJ Open · 2022-Apr-01 The study is a Phase III RCT but lacks a drug intervention (ICG is an imaging agent, not a therapeutic drug) and a primary time-to-event efficacy endpoint (primary endpoint is clinical anastomotic leakage, a binary safety/complication outcome). It is a protocol without reported results. |
H
L
S
B
|
旧组与严格 v3 交集 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Response prediction and risk stratification of patients with rectal cancer after neoadjuvant therapy through an analysis of circulating tumour DNA. PMID 35306340 · EBioMedicine · 2022-Apr The record describes a secondary/biomarker analysis from a phase II/III randomized trial in rectal cancer. While it meets criteria for oncology, human, randomized, phase, and time-to-event endpoint, the specific intervention (neoadjuvant therapy) is not defined as a drug-containing regimen in the provided abstract. Without explicit evidence of a drug intervention, it cannot be confirmed as eligible. |
H
L
S
B
|
旧组与严格 v3 交集 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer. PMID 35177277 · Gynecol Oncol · 2022-Apr The record describes a randomized trial in oncology with a drug intervention and a time-to-event endpoint (PFS with HR). However, the abstract and metadata do not explicitly state the trial phase (e.g., 'Phase III'), making it impossible to confirm the 'phase3_or_definitive' criterion with certainty. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study. PMID 35115180 · Gynecol Oncol · 2022-Apr This is a formal report of a subgroup analysis from a Phase III randomized trial evaluating olaparib maintenance therapy in BRCA-mutated ovarian cancer. It meets all core eligibility criteria: oncology, human, randomized, Phase III, drug intervention (olaparib), and primary time-to-event efficacy endpoints (PFS, OS) with HR analysis. The report is original and presents results from the pre-specified SOLO2 trial cohort, not a post-hoc biomarker-only or safety-only analysis. |
H
L
S
B
|
旧组与严格 v3 交集 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66]. PMID 35086737 · Ann Oncol · 2022-Apr The record is a corrigendum (erratum) to a Phase III RCT. The metadata confirms it is oncology, randomized, and Phase III, but it is not an original result report and does not contain time-to-event efficacy data itself. The original trial (ITACA) is eligible, but this specific record is a secondary administrative document. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta-analysis of randomized clinical trials. PMID 34940983 · Hematol Oncol · 2022-Apr The record describes a network meta-analysis focused on the safety endpoint of cardiotoxicity. It does not report primary or key secondary time-to-event efficacy endpoints (like OS, PFS) from an original randomized trial, making it ineligible. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2. PMID 34420143 · Qual Life Res · 2022-Apr The record describes a methodological study on missing data for adverse event reporting in two phase III oncology trials. While the underlying trials are oncology, randomized, phase III, and drug-interventional, this specific publication does not present the primary or key secondary time-to-event efficacy results (e.g., OS, PFS) from those trials. It is a secondary analysis focused on statistical methods for PRO-CTCAE data, which falls under the 'other' report type for this adjudication context and is excluded. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Beyond diabetes mellitus: role of metformin in non-muscle-invasive bladder cancer. PMID 32798360 · Singapore Med J · 2022-Apr The study is a randomized, double-blind, controlled trial with drug intervention (metformin) and time-to-event endpoints (OS, DSS) in oncology. However, the primary objective of the trial was not metformin but BCG (intravesical Bacille Calmette-Guerin); metformin use was a subgroup analysis within this trial. The abstract does not explicitly state the trial phase, and it is not a Phase III/IIIb or Phase II/III trial of a drug-containing intervention. It is a secondary analysis of a randomized trial, not a primary report of a definitive drug trial. Therefore, eligibility is uncertain. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Landmark mediation survival analysis using longitudinal surrogate. PMID 36733365 · Front Oncol · 2022 This is a methodological/analytical article describing a statistical framework (landmark mediation survival analysis) for integrating longitudinal tumor burden data. While it references 'two colorectal cancer trials' and discusses time-to-event outcomes like survival, it is not a report of original trial results. It does not present a specific randomized comparison of drug interventions with a primary efficacy endpoint (e.g., OS, PFS) in a Phase III setting. The abstract focuses on statistical methodology, not on reporting the results of a definitive randomized trial. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial. PMID 36480560 · PLoS One · 2022 The record describes a randomized, oncology (prostate cancer), human trial with a drug intervention (rosuvastatin) and a primary time-to-event endpoint (OS) analyzed via Kaplan-Meier. However, the explicit trial phase (III/IIIb or II/III) is not stated in the provided metadata. The deterministic review flagged 'phase3_evidence_unclear'. Without explicit phase confirmation, eligibility cannot be definitively established. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: Trial protocol of the randomized Neo-ACT trial. PMID 36227931 · PLoS One · 2022 The record is a trial protocol with no reported results. While it is randomized, involves a drug intervention (neoadjuvant chemotherapy), and has time-to-event endpoints listed as secondary outcomes, it does not meet the criterion of being an original formal-result report of a trial. The phase is also not explicitly stated as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Application of VIP Care in Patients with Advanced Tumors in the Western Region of China. PMID 36093398 · Biomed Res Int · 2022 Study is a randomized controlled trial in oncology patients but lacks a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). The primary endpoint is quality of life and decision-making. The phase is not specified as Phase III/IIIb or Phase II/III. Therefore, it does not meet the eligibility criteria. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Comparative analyses of paclitaxel/carboplatin with cisplatin/5-fluorouracil-based chemoradiation in locally advanced inoperable upper and middle third esophageal cancer: A randomized prospective pilot study. PMID 35900549 · J Cancer Res Ther · 2022 The study is an oncology randomized controlled trial with a drug intervention and original results. However, it is explicitly described as a 'pilot study', and the abstract does not report a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier curve). The deterministic review also flagged 'no_time_to_event_signal'. Therefore, it fails the 'time_to_event' and 'phase3_or_definitive' criteria. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines. PMID 35898703 · Oncoimmunology · 2022 The record is a pooled biomarker analysis abstract summarizing results from three separate trials (SLU01, SOV01, SP005). It does not present the primary formal efficacy results of a single Phase III/IIIb or Phase II/III randomized trial with a drug intervention and a primary time-to-event endpoint. Therefore, it is not eligible as an original result report for KM digitization. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. PMID 35769948 · Oncoimmunology · 2022 The record is a preclinical/experimental journal article that discusses and interprets two published phase III clinical trials. It is not an original formal-result report of a human malignant-neoplasm Phase III/IIIb or Phase II/III randomized trial with a drug intervention and a primary/key secondary time-to-event efficacy endpoint. The deterministic review signal 'no_time_to_event_signal' is correct for this record as a potential source of trial data. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Curcumin on Treating Cancer Anorexia-Cachexia Syndrome in Locally or Advanced Head and Neck Cancer: A Double-Blind, Placebo-Controlled Randomised Phase IIa Trial (CurChexia). PMID 35694030 · J Nutr Metab · 2022 This is a Phase IIa trial for a supportive care endpoint (cachexia) using curcumin, a dietary supplement, with no time-to-event efficacy outcome. It fails multiple key eligibility criteria: non-definitive phase, non-drug intervention, and absence of required time-to-event endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Registered Clinical Trials Comprising Pregnant Women in China: A Cross-Sectional Study. PMID 35450038 · Front Pharmacol · 2022 The provided record is a cross-sectional, descriptive study of clinical trial registrations in China. It is not an original report of a clinical trial's results, does not contain any time-to-event efficacy data, and does not meet any of the core eligibility criteria for an oncology Kaplan-Meier digitization cohort. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Three-Dimensional Ultrasound Images in the Assessment of Bladder Tumor Health Monitoring under Deep Learning Algorithms. PMID 35371287 · Comput Math Methods Med · 2022 The record describes a randomized trial on bladder cancer that compares a health monitoring model with an imaging algorithm. However, it lacks explicit phase information for a definitive trial (e.g., Phase III), does not report a time-to-event efficacy endpoint (like OS, PFS, or HR), and does not involve a drug intervention. The primary outcomes are image quality, quality of life, satisfaction, and complications, not the specified efficacy endpoints. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Sequential Capecitabine on Adjuvant Chemotherapy of Triple-Negative Breast Cancer. PMID 35265304 · J Healthc Eng · 2022 Phase of trial is not explicitly stated in the provided metadata. While it is a randomized controlled trial with drug intervention and time-to-event endpoints, the phase (II/III or III) cannot be confirmed from the title, abstract, or publication types, which is required for eligibility. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Clinical research in oncology: in memory of Professor Gordon McVie. PMID 35242221 · Ecancermedicalscience · 2022 The record is an article summarizing common problems in drug development, referencing phase 3 randomized trials but not presenting original trial results with a primary or key secondary time-to-event endpoint (OS, PFS, DFS, etc.). It is not an original result report. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy comparison of optimal treatments for hepatocellular carcinoma patients with portal vein tumor thrombus. PMID 34614432 · Ann Hepatol · 2022 The study is a retrospective analysis comparing three real-world treatment cohorts (liver resection, TACE, sorafenib). While the publication types include 'Randomized Controlled Trial', the methods describe retrospective recruitment and random division into training/validation cohorts for analysis, not a prospective randomized trial of a drug intervention against a control. There is no evidence that this is a Phase III/IIIb or Phase II/III randomized trial of a drug intervention. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial. PMID 34579775 · Cardiooncology · 2021-Sep-27 Eligibility criteria cannot be fully established: the record is a protocol abstract for an ongoing trial with no reported results. The primary endpoint is a change in left ventricular ejection fraction (LVEF), which is not a time-to-event efficacy endpoint. Furthermore, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial. PMID 34219148 · Br J Surg · 2021-Sep-27 The record is a published erratum for a biomarker analysis within a randomized trial, not an original report of a Phase III/IIIb trial with a drug intervention and a primary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. PMID 34525968 · BMC Cancer · 2021-Sep-15 The record is a correction (erratum) to a trial abstract, and the abstract itself is empty. While the title suggests eligibility, the absence of an abstract prevents verification of human subjects, time-to-event endpoints, and original result status. The record is therefore ineligible as a primary result report. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Long-Term Outcomes and Sites of Failure in Locally Advanced, Cervical Cancer Patients Treated by Concurrent Chemoradiation with or without Adjuvant Chemotherapy: ACTLACC Trial. PMID 34582670 · Asian Pac J Cancer Prev · 2021-Sep-01 The record meets most criteria (oncology, human, randomized, drug intervention, time-to-event endpoint, original result), but the trial phase cannot be confirmed as Phase III/IIIb or Phase II/III from the provided metadata. The title and abstract do not mention the phase, and the publication type 'Randomized Controlled Trial' does not specify the phase. Therefore, eligibility cannot be fully established. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Characteristics and Research Waste Among Randomized Clinical Trials in Gastric Cancer. PMID 34533573 · JAMA Netw Open · 2021-Sep-01 The record is a cross-sectional bibliometric analysis of gastric cancer RCTs, not an original report of results from a single randomized trial. It does not present time-to-event efficacy data for a specific drug intervention. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma. PMID 33846198 · Clin Cancer Res · 2021-Sep-01 While the record describes an eligible randomized oncology trial with a drug intervention and time-to-event endpoints, it is an FDA approval summary, not the original primary result report. Furthermore, the trial phase is not explicitly stated in the provided metadata, preventing confirmation of the phase3_or_definitive criterion. Therefore, eligibility cannot be established. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A three-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma. PMID 32817282 · Haematologica · 2021-Sep-01 The record describes a retrospective biomarker study that uses data from randomized trials but does not constitute the original formal report of a trial's primary or key secondary efficacy results. The drug intervention (bortezomib) is only analyzed in an exploratory subgroup, and the report's primary aim is prognostic signature validation, not trial result dissemination. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Propofol decreases CD8+ T cells and sevoflurane increases regulatory T cells after lung cancer resection: a randomized controlled trial. PMID 34659809 · J Thorac Dis · 2021-Sep The study is a randomized trial in oncology patients but does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). It focuses on immunological outcomes (flow cytometry of T cell subsets) as a primary endpoint. The intervention compares anesthetic agents (propofol, sevoflurane, desflurane) which are drugs, but the study's primary outcome is not a clinical efficacy endpoint (time-to-event) but a pharmacodynamic/immunologic effect. Therefore, it does not meet the core inclusion criteria for a drug-containing intervention trial with a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Prognostic and Predictive Value of Tumor Budding in Colorectal Cancer. PMID 34099382 · Clin Colorectal Cancer · 2021-Sep The record describes a secondary biomarker analysis from a randomized trial. While it is oncology, human, randomized, involves a drug intervention, and reports time-to-event outcomes, it fails two key eligibility criteria: (1) the trial phase is not explicitly established, and (2) it is not the original primary result report of the trial but a secondary analysis focusing on a biomarker's prognostic and predictive value. The time-to-event endpoints are analyzed as secondary outcomes within this biomarker study, not as the primary/time-to-event efficacy endpoint of the original trial. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial. PMID 33320286 · Strahlenther Onkol · 2021-Sep The record describes a randomized Phase III oncology trial (HYPOSIB) comparing hypofractionated vs. standard radiotherapy regimens. However, it is ineligible because: 1) The intervention is non-drug (radiotherapy), 2) The reported outcomes are adoption patterns and patient characteristics, not time-to-event efficacy endpoints (OS, PFS, etc.), and 3) The abstract does not present original trial efficacy results (e.g., Kaplan-Meier curves, hazard ratios). |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |